Toxicity

Request a toxicity pilot study plan and quote to evaluate local tolerance and immune effects in ex vivo human skin models.

Download this application note and discover 3 case studies. Refine formulations or assess local tolerance in human skin before clinical trials.

Explore how HypoSkin®—a standardized, injectable, and immunocompetent human skin model—provides a translational, animal-free solution for assessing the immunogenicity of therapeutic compounds. From structural stability to real-time immune response profiling, this white paper delivers data-backed insights designed for pharma and biotech teams advancing injectable drug development.

Top-level science through the eyes of an expert.Join us for the next session in Genoskin’s webinar series, where we explore cutting-edge advancements in drug delivery and therapeutic innovation. This session will feature an in-depth presentation on polymer prodrug nanocarriers, showcasing a novel approach to controlled and efficient drug release. Watch the replayThis webinar explores new research on polymer-drug conjugates inRead more

Genoskin at the SOT 64th Annual Meeting and ToxExpoAdvancing non-clinical toxicity assessment with ex vivo human skin and mast cell models We are excited to participate in the SOT 64th Annual Meeting and ToxExpo, taking place from March 16-20, 2025, at the Orange County Convention Center in Orlando, Florida. As one of the most influential events in toxicology, this meetingRead more

From human skin to human data: Advancing immunogenicity testing with human modelsIn a public workshop organized by the FDA-CRCG group, Dr. Nicolas Gaudenzio, CSO of Genoskin, introduced an innovative platform for assessing immune reactions in response to injected substances using human skin explants. His talk, titled "A new in vitro framework for assessing immunogenicity using comprehensive profiling of injectable humanRead more